Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- SPRINGIndependent statistical analysis of High-Risk Neuroblastoma Chemotherapy Without G-CSF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02786719).
- STAR-TRECIndependent statistical analysis of STAR-TREC (NCT02945566), a randomized phase 2/3 trial evaluating organ preservation strategies versus total mesorectal excision for early rectal cancer.
- STARSIndependent statistical analysis of A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- STARTComplete statistical analysis of START, a randomized phase 3 trial of tecemotide (L-BLP25) plus cyclophosphamide versus saline plus placebo in unresectable stage III non-small cell lung cancer, including overall survival, symptom progression,…
- STARTRK-1Independent statistical analysis of STARTRK-1, a phase 1 study of entrectinib in adult patients with locally advanced or metastatic solid tumors with NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alterations.
- STARTRK-NGIndependent statistical analysis of STARTRK-NG (NCT02650401), a phase 1/2 study of entrectinib in children and adolescents with locally advanced or metastatic solid tumors and CNS tumors.
- STOMPIndependent statistical analysis of STOMP (NCT02343042), a randomized phase 1/2 study evaluating selinexor with backbone treatments in patients with multiple myeloma, including dose-escalation, pharmacokinetic, response, and duration-of-response endpoints.
- STORMIndependent statistical analysis of the STORM phase 2 trial of selinexor and dexamethasone in multiple myeloma, including its non-randomized design, overall response rate endpoint, statistical methodology, and safety reporting.
- SUCCESS CA statistical analysis of SUCCESS C, a phase 3 randomized breast cancer trial evaluating docetaxel-based adjuvant treatment strategies and disease-free survival methodology.
- SUN1058Independent statistical analysis of A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone: primary endpoint results, effect estimate with confidence interval,…
- SURTIMEIndependent statistical analysis of the SURTIME phase 3 trial of immediate surgery or surgery after sunitinib malate in metastatic kidney cancer, including trial design, progression-free survival, planned analysis, statistical interpretation, and limitations.
- SWOG 9346Independent statistical analysis of SWOG 9346, a randomized phase 3 trial of intermittent versus continuous hormonal therapy in men with stage IV prostate cancer, including overall survival and 3-month functional outcomes.
- Symptoms-StepsIndependent statistical analysis of In Person and mHealth Coping Skills Training for Symptom Management and Steps in Stem Cell Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- TAILORIndependent statistical analysis of the TAILOR phase 3 trial evaluating erlotinib versus docetaxel in non small cell lung cancer, including trial design, endpoints, planned statistical methods, and interpretation.
- TAPIndependent statistical analysis of Postoperative Pain Control for Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00913068).
- TARGETIndependent statistical analysis of Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TAS3351Independent statistical analysis of A Study of TAS3351 in NSCLC Patients With EGFRmt: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05765734).
- TASCO1Independent statistical analysis of TASCO1 (NCT02743221), a randomized phase 2 study comparing trifluridine/tipiracil plus bevacizumab with capecitabine plus bevacizumab in previously untreated metastatic colorectal cancer patients non-eligible for intensive therapy.
- TATTONIndependent statistical analysis of the phase 1 TATTON trial of AZD9291 in combination with AZD6094 or selumetinib in advanced non-small-cell lung cancer, including trial design, safety endpoints, planned analysis, and statistical interpretation.
- TAX316Complete statistical analysis of TAX316, a randomized phase 3 trial comparing docetaxel-containing TAC with FAC in node-positive adjuvant breast cancer, including disease-free survival, overall survival, statistical methodology, safety, and interpretation.
- TAXYNERGYIndependent statistical analysis of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC): primary endpoint results, effect estimate with…
- TEAMIndependent statistical analysis of TEAM, the randomized phase 3 trial comparing exemestane with tamoxifen followed by exemestane in postmenopausal patients with receptor-positive breast cancer. Includes disease-free survival, overall survival, time to relapse,…
- TEAMIndependent statistical analysis of A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TEXTIndependent statistical analysis of TEXT, a randomized phase 3 trial of triptorelin with either exemestane or tamoxifen in premenopausal women with hormone-responsive breast cancer, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank…
- TheraPAn independent statistical analysis of the TheraP randomized phase 2 trial of 177Lu-PSMA617 versus cabazitaxel in progressive metastatic castration resistant prostate cancer, including trial design, PSA response endpoint, planned statistical analysis, and…
- THORIndependent statistical analysis of A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations: primary endpoint…
- TIVO-1An independent statistical analysis of the phase 3 TIVO-1 trial comparing tivozanib with sorafenib in subjects with advanced renal cell carcinoma, including trial design, the registered progression-free survival endpoint, planned statistical analysis,…
- TIVO-1Independent statistical analysis of A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TK008Independent statistical analysis of Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- TK112690Independent statistical analysis of Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- TNBCIndependent statistical analysis of Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TNTIndependent statistical analysis of the phase 3 TNT trial of carboplatin and docetaxel in breast cancer, including its crossover design, response endpoint, planned analysis, and statistical interpretation.
- TOP 1501Independent statistical analysis of Neoadjuvant Pembrolizumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02818920).
- TOP1201 IPIIndependent statistical analysis of Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence…
- TOPAZIndependent statistical analysis of Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.: primary endpoint results, effect estimate with confidence interval, sample-size…
- TOPAZ-1Independent statistical analysis of Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- TOPSIndependent statistical analysis of Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity): primary endpoint results, effect…
- TRAILIndependent statistical analysis of Letrozole for Lymphangioleiomyomatosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01353209).
- TRAIN-2Independent statistical analysis and educational interpretation of TRAIN-2, a randomized phase 3 trial evaluating neoadjuvant chemotherapy strategies with pertuzumab in HER2-positive breast cancer.
- TRANSCEND NHL 001An independent statistical analysis of TRANSCEND NHL 001 (NCT02631044), evaluating JCAR017 single-dose and 2-dose schedules in B-cell non-Hodgkin lymphoma, with emphasis on safety, dose-limiting toxicity, and objective response rate.
- TRANSFORMIndependent statistical analysis of the randomized phase 3 TRANSFORM trial of JCAR017 versus standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas.
- TremelimumabIndependent statistical analysis of Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- TRIBEIndependent statistical analysis of TRIBE (NCT00719797), a phase 3 randomized trial comparing bevacizumab with FOLFOXIRI versus bevacizumab with FOLFIRI as first-line therapy for metastatic colorectal cancer.
- TRINITI-1An independent statistical analysis of TRINITI-1, evaluating ribociclib with everolimus and exemestane in HR+ HER2- locally advanced or metastatic breast cancer after progression on a CDK 4/6 inhibitor.
- TRINOVA-1Independent statistical analysis of TRINOVA-1, a phase 3 randomized trial evaluating AMG 386 or placebo with weekly paclitaxel chemotherapy in ovarian, primary peritoneal, and fallopian tube cancer.
- TRINOVA-2Independent statistical analysis of the randomized phase 3 TRINOVA-2 trial evaluating AMG 386 (trebananib) plus PLD versus placebo plus PLD in ovarian cancer and related gynecologic cancers.
- TRITON3Independent statistical analysis of A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency: primary endpoint results, effect estimate with confidence…
- TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.
- TULIPIndependent statistical analysis of the phase 3 TULIP trial of (vic-)trastuzumab duocarmazine versus physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer, including progression-free survival, overall survival, response, quality…
- Tx-TreatmentIndependent statistical analysis of Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…